Joakim Tedroff

3.4k total citations · 1 hit paper
86 papers, 2.5k citations indexed

About

Joakim Tedroff is a scholar working on Cellular and Molecular Neuroscience, Neurology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Joakim Tedroff has authored 86 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 60 papers in Cellular and Molecular Neuroscience, 50 papers in Neurology and 12 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Joakim Tedroff's work include Neurological disorders and treatments (39 papers), Neuroscience and Neuropharmacology Research (36 papers) and Parkinson's Disease Mechanisms and Treatments (33 papers). Joakim Tedroff is often cited by papers focused on Neurological disorders and treatments (39 papers), Neuroscience and Neuropharmacology Research (36 papers) and Parkinson's Disease Mechanisms and Treatments (33 papers). Joakim Tedroff collaborates with scholars based in Sweden, United States and Italy. Joakim Tedroff's co-authors include Per Hartvig, Nicholas Waters, Bengt Långström, Arvid Carlsson, Maria Carlsson, Marie K. L. Nilsson, Peter Bjurling, Sten‐Magnus Aquilonius, Richard Torstenson and B. L�ngstr�m and has published in prestigious journals such as Neurology, Annals of Neurology and The Lancet Neurology.

In The Last Decade

Joakim Tedroff

85 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Interactions Between Monoamines, Glutamate, and GABA in Schizophrenia: New Evidence

2001 527 citations Arvid Carlsson, Nicholas Waters et al. profile →

Peers

Countries citing papers authored by Joakim Tedroff

Since Specialization

Citations

This map shows the geographic impact of Joakim Tedroff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joakim Tedroff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joakim Tedroff more than expected).

Fields of papers citing papers by Joakim Tedroff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joakim Tedroff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joakim Tedroff. The network helps show where Joakim Tedroff may publish in the future.

Co-authorship network of co-authors of Joakim Tedroff

This figure shows the co-authorship network connecting the top 25 collaborators of Joakim Tedroff. A scholar is included among the top collaborators of Joakim Tedroff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joakim Tedroff. Joakim Tedroff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Mesdopetam for the Treatment of Levodopa Induced Dyskinesia in Parkinson's Disease: A Randomized Phase 2b Trial 2025 ·Movement Disorders Clinical Practice ·Angelo Antonini, Padraig O’Suilleabhain, Fabrizio Stocchi, (unknown), Nicholas Waters, Clas Sonesson, Joakim Tedroff	4
2	Neurophysiological Treatment Effects of Mesdopetam, Pimavanserin and Amantadine in a Rodent Model of Levodopa‐Induced Dyskinesia 2025 ·European Journal of Neuroscience ·(unknown), Tiberiu Loredan Stan, (unknown), Pär Halje, Azat Nasretdinov, (unknown), Sebastian Sulis Sato, (unknown), Joakim Tedroff, Nicholas Waters, Per Petersson	0
3	(3S)‐3‐(2,3‐difluorophenyl)‐3‐methoxypyrrolidine (IRL752) —a Novel Cortical-Preferring Catecholamine Transmission- and Cognition-Promoting Agent 2020 ·Journal of Pharmacology and Experimental Therapeutics ·Stephan Hjorth, Nicholas Waters, Joakim Tedroff, Peder Svensson, (unknown), (unknown), (unknown), E. Ljung, (unknown), Samantha L. McLean, Ben Grayson, Nagi Idris, Joanna C. Neill, Clas Sonesson	4
4	Preclinical Pharmacology of [2-(3-Fluoro-5-Methanesulfonyl-phenoxy)Ethyl](Propyl)amine (IRL790), a Novel Dopamine Transmission Modulator for the Treatment of Motor and Psychiatric Complications in Parkinson Disease 2020 ·Journal of Pharmacology and Experimental Therapeutics ·Nicholas Waters, Clas Sonesson, Peder Svensson, Joakim Tedroff, Manolo Carta, E. Ljung, (unknown), (unknown), (unknown), (unknown), (unknown), Stephan Hjorth	18
5	Effects of a Novel Psychomotor Stabilizer, IRL790, on Biochemical Measures of Synaptic Markers and Neurotransmission 2020 ·Journal of Pharmacology and Experimental Therapeutics ·Kristina Bečanović, (unknown), Vasco C. Sousa, Joakim Tedroff, Per Svenningsson	2
6	Pridopidine: Overview of Pharmacology and Rationale for its Use in Huntington’s Disease 2018 ·Journal of Huntington s Disease ·Nicholas Waters, Joakim Tedroff, (unknown), Daniel Klamer, Clas Sonesson	20
7	The dopaminergic stabilizer pridopidine is to a major extent N-depropylated by CYP2D6 in humans 2012 ·European Journal of Clinical Pharmacology ·Anders Helldén, Georgios Panagiotidis, Petter Johansson, Nicholas Waters, Joakim Tedroff, Leif Bertilsson	3
8	PND38 International Comparison of Huntington Disease (HD) Burden 2011 ·Value in Health ·J Dorey, (unknown), Joakim Tedroff, Ferdinando Squitieri, E. Clay, (unknown), Daniel Zielonka, Jordan J. Cohen, Samuel Aballéa, Michel Lamure, Mondher Toumi	2
9	Different corticostriatal patterns of L‐DOPA utilization in patients with untreated schizophrenia and patients treated with classical antipsychotics or clozapine 2003 ·Scandinavian Journal of Psychology ·О. Гефверт, Leif Lindström, Nicholas Waters, Arvid Carlsson, Joakim Tedroff	20
10	PNU-96391A (OSU6162) antagonizes the development of behavioral sensitization induced by dopamine agonists in a rat model for Parkinson’s Disease 2002 ·Neuropharmacology ·(unknown), Maria Cimini, Joseph V. Haas, Brian A. Staton, Joakim Tedroff, Kjell Svensson	12
11	NMDA‐Receptor Activity Visualized with (S)‐[N‐Methyl‐¹¹C]Ketamine and Positron Emission Tomography in Patients with Medial Temporal Lobe Epilepsy 1999 ·Epilepsia ·Eva Kumlien, Per Hartvig, Sven Valind, Ivar Øye, Joakim Tedroff, Bengt Långström	62
12	Absorption of l-DOPA from the proximal small intestine studied in the rhesus monkey by positron emission tomography. 1999 ·European Journal of Pharmaceutical Sciences ·Dag Nilsson, Hans Lennernäs, (unknown), Anders Sundin, Joakim Tedroff, Sten‐Magnus Aquilonius, Per Hartvig, Bengt Långström	4
13	Effect of apomorphine infusion on dopamine synthesis rate relates to dopaminergic tone 1998 ·Neuropharmacology ·Richard Torstenson, Per Hartvig, Bengt Långström, (unknown), Gunnar Antoni, Joakim Tedroff	26
14	OSU6182 a representative from a unique class of functional modulators of dopaminergic systems 1997 ·The Society for Neuroscience Abstracts ·Clas Sonesson, Joakim Tedroff, (unknown), Anna‐Carin C. Carlsson, Lennart Hansson, Nicholas Waters	3
15	Synthesis of [11C-methyl]-(−)-OSU6162, its regional brain distribution and some pharmacological effects of (−)-OSU6162 on the dopaminergic system studied in the rhesus monkey by positron emission tomography 1997 ·Nuclear Medicine and Biology ·(unknown), Per Hartvig, Richard Torstenson, (unknown), Clas Sonesson, Nicholas Waters, Arvid Carlsson, Joakim Tedroff, Bengt Långström	13
16	Neurological Wilson's disease studied with magnetic resonance imaging and with positron emission tomography using dopaminergic markers 1995 ·Movement Disorders ·Kerstin Westermark, Joakim Tedroff, (unknown), Per Hartvig, Bengt Långström, Yvonne Andersson, (unknown), Sten‐Magnus Aquilonius	33
17	Pyridoxine effect on synthesis rate of serotonin in the monkey brain measured with positron emission tomography 1995 ·Journal of Neural Transmission ·Per Hartvig, Karl‐Johan Lindner, Peter Bjurling, B. L�ngstr�m, Joakim Tedroff	46
18	PET STUDIES WITH l-[11C]5-HTP AND l-[11C]DOPA IN BRAINS OF HEALTHY VOLUNTEERS AND PATIENTS WITH MAJOR DEPRESSION 1992 ·Clinical Neuropharmacology ·(unknown), (unknown), Per Hartvig, Joakim Tedroff, Peter Bjurling, Hans Lundqvist, Bengt Långström	6
19	Regional brain kinetics of 6-fluoro-(?-11C)-L-dopa and (?-11C)-L-dopa following COMT inhibition. A study in vivo using positron emission tomography 1992 ·Journal of Neural Transmission ·Per Hartvig, Karl‐Johan Lindner, Joakim Tedroff, Peter Bjurling, (unknown), B. L�ngstr�m	33
20	Pharmacokinetics and effects of levodopa in advanced Parkinson's disease 1990 ·European Journal of Clinical Pharmacology ·Eva Bredberg, Joakim Tedroff, S.‐M. Aquilonius, L Paalzow	37

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact